Literature DB >> 17106492

Stage III colon cancer at Baylor University Medical Center at Dallas and the Baylor Sammons Cancer Center: experience from 2000 to 2004.

A David McCollum1.   

Abstract

Entities:  

Year:  2006        PMID： 17106492      PMCID： PMC1618738          DOI： 10.1080/08998280.2006.11928193

Source DB:  PubMed          Journal:  Proc (Bayl Univ Med Cent)        ISSN： 0899-8280


× No keyword cloud information.
  14 in total

Review 1.  NIH consensus conference. Adjuvant therapy for patients with colon and rectal cancer.

Authors: 
Journal:  JAMA       Date:  1990-09-19       Impact factor: 56.272

2.  Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.

Authors:  P M Hoff; R Ansari; G Batist; J Cox; W Kocha; M Kuperminc; J Maroun; D Walde; C Weaver; E Harrison; H U Burger; B Osterwalder; A O Wong; R Wong
Journal:  J Clin Oncol       Date:  2001-04-15       Impact factor: 44.544

3.  Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.

Authors:  E Van Cutsem; C Twelves; J Cassidy; D Allman; E Bajetta; M Boyer; R Bugat; M Findlay; S Frings; M Jahn; J McKendrick; B Osterwalder; G Perez-Manga; R Rosso; P Rougier; W H Schmiegel; J F Seitz; P Thompson; J M Vieitez; C Weitzel; P Harper
Journal:  J Clin Oncol       Date:  2001-11-01       Impact factor: 44.544

4.  Adjuvant chemotherapy for stage III colon cancer: implications of race/ethnicity, age, and differentiation.

Authors:  J Milburn Jessup; Andrew Stewart; Frederick L Greene; Bruce D Minsky
Journal:  JAMA       Date:  2005-12-07       Impact factor: 56.272

Review 5.  Colon cancer screening strategies.

Authors:  Jaya Agrawal; Sapna Syngal
Journal:  Curr Opin Gastroenterol       Date:  2005-01       Impact factor: 3.287

6.  The growth and maturation of the National Cancer Data Base.

Authors:  H R Menck; M P Cunningham; J M Jessup; H J Eyre; D P Winchester; C E Scott-Conner; G P Murphy
Journal:  Cancer       Date:  1997-12-15       Impact factor: 6.860

7.  Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.

Authors:  A de Gramont; A Figer; M Seymour; M Homerin; A Hmissi; J Cassidy; C Boni; H Cortes-Funes; A Cervantes; G Freyer; D Papamichael; N Le Bail; C Louvet; D Hendler; F de Braud; C Wilson; F Morvan; A Bonetti
Journal:  J Clin Oncol       Date:  2000-08       Impact factor: 44.544

8.  A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.

Authors:  Richard M Goldberg; Daniel J Sargent; Roscoe F Morton; Charles S Fuchs; Ramesh K Ramanathan; Stephen K Williamson; Brian P Findlay; Henry C Pitot; Steven R Alberts
Journal:  J Clin Oncol       Date:  2003-12-09       Impact factor: 44.544

9.  Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.

Authors:  Thierry André; Corrado Boni; Lamia Mounedji-Boudiaf; Matilde Navarro; Josep Tabernero; Tamas Hickish; Clare Topham; Marta Zaninelli; Philip Clingan; John Bridgewater; Isabelle Tabah-Fisch; Aimery de Gramont
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

10.  Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma.

Authors:  C G Moertel; T R Fleming; J S Macdonald; D G Haller; J A Laurie; P J Goodman; J S Ungerleider; W A Emerson; D C Tormey; J H Glick
Journal:  N Engl J Med       Date:  1990-02-08       Impact factor: 91.245
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.